Cite Filings / LXEO / 0002012383-25-002600
Feed Companies Filings Check
Sign in
SCHEDULE 13G/A

Statement of Beneficial Ownership

Lexeo Therapeutics, Inc. · Filed 2025-10-17 · Acc 0002012383-25-002600

Documents 1

  • SCHEDULE 13G/A Statement of Beneficial Ownership , xslSCHEDULE_13G_X01/primary_doc.xml

Around this filing

  • 2025-11-07 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2025-10-17 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2025-10-17 144 Sale of Securities
  • 2025-10-17 144 Sale of Securities
  • 2025-10-17 8-K Material agreement · Results of operations · Unregistered share sale · Other events
  • 2025-10-17 424B5 Prospectus
  • 2025-08-14 SCHEDULE 13G/A Statement of Beneficial Ownership

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G/A · JANUS HENDERSON GROUP Ltd. 7.2%
  2. 2026-11-16 SCHEDULE 13G/A · BALYASNY ASSET MANAGEMENT L.P. 9.99%
  3. 2026-11-16 SCHEDULE 13G/A · Paradigm BioCapital Advisors LP 0.0%
  4. 2026-11-16 SCHEDULE 13G/A · OrbiMed Advisors LLC 3.9%
  5. 2026-11-16 SCHEDULE 13G/A · Vestal Point Capital, LP 6.3%
  6. 2026-11-13 SCHEDULE 13G/A · Affinity Asset Advisors, LLC 9.8%
Loading xslSCHEDULE_13G_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…